Overview

A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2028-07-31

Target enrollment:

Participant gender:

Summary

The PORTAL study will test a new combination of drugs (glofitamab, polatuzumab vedotin and obinutuzumab) in patients with large B-cell lymphoma (LBCL) that has come back (relapsed) or not responded to previous treatment. It will determine how safe and effective the combination of these cancer drugs is in treating LBCL before and after CAR-T cell therapy.

Phase:

Phase 2

Details

Lead Sponsor:

University College, London

Collaborator:

Hoffmann-La Roche

Treatments:

Obinutuzumab
Polatuzumab vedotin